Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624131 | 0.78 | TYK2 (0.38) | FABP4FABP5TYK2NPSR1NOS3 | |
| SCHEMBL2624120 | 0.76 | TYK2 (0.35) | FABP4FABP5TYK2CYP2C9 | |
| SCHEMBL2117929 | 0.74 | TYK2 (0.35) | FABP4FABP5TYK2IDH1CYP2C9 | |
| SCHEMBL2624096 | 0.72 | TNKS (0.47) | TYK2MEN1TSHRKMT2ACYP2C9 | |
| SCHEMBL20609522 | 0.69 | NPSR1 (0.41) | NPSR1NOS3NOS1NOS2MEN1 | |
| SCHEMBL2861979 | 0.68 | CCR4 (0.41) | MEN1TSHRKMT2ACYP2C9 | |
| SCHEMBL2116011 | 0.66 | IDH1 (0.33) | TYK2IDH1 | |
| SCHEMBL6075839 | 0.66 | KDM4E (0.44) | CYP2C9 | |
| SCHEMBL27013361 | 0.65 | LMNA (0.56) | TSHR | |
| SCHEMBL6077104 | 0.64 | ACHE (0.38) | NOS3NOS1NOS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | FABP4 4134/4885FABP5 4216/4885TYK2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.